Momate Nasal Spray Overdosage

There are no data available on the effects of acute or chronic overdosage with Mometasone furoate monohydrate Nasal Spray 50 mcg. Because of low systemic bioavailablity and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation. Intranasal administration of 1600 mcg (4 times the recommended dose of Mometasone furoate monohydrate Nasal Spray 50 mcg for the treatment of nasal polyps in patients 18 years of age and older) daily for 29 days to healthy human volunteers showed no increased incidence of adverse events. Single intranasal doses up to 4000 mcg and oral inhalation doses up to 8000 mcg have been studied in human volunteers with no adverse effects reported. Chronic overdosage with any corticosteroid may result in signs or symptoms of hypercorticism. Acute overdosage with this dosage form is unlikely since one bottle of Mometasone furoate monohydrate Nasal Spray 50 mcg contains approximately 8500 mcg of mometasone furoate.